Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007649 | 0.84 | MEN1 (0.35) | PDE4AMEN1KMT2AASAH1OR51E2 | |
| SCHEMBL9007655 | 0.84 | MEN1 (0.35) | PDE4AMEN1KMT2AASAH1OR51E2 | |
| SCHEMBL18981606 | 0.84 | PDE4A (0.50) | PDE4AMEN1KMT2AASAH1LMNA | |
| SCHEMBL4330104 | 0.81 | MEN1 (0.37) | MEN1KMT2AASAH1OR51E2DEGS1 | |
| SCHEMBL4330244 | 0.81 | MEN1 (0.37) | MEN1KMT2AASAH1OR51E2DEGS1 | |
| SCHEMBL3743604 | 0.78 | PAX8 (0.38) | MEN1KMT2AASAH1LMNAOR51E2 | |
| SCHEMBL16468486 | 0.78 | PAX8 (0.38) | MEN1KMT2AASAH1LMNAOR51E2 | |
| SCHEMBL20572594 | 0.78 | PAX8 (0.38) | MEN1KMT2AASAH1LMNAOR51E2 | |
| SCHEMBL5936379 | 0.78 | MAPT (0.45) | PDE4AMEN1KMT2AASAH1LMNA | |
| SCHEMBL5936381 | 0.78 | MAPT (0.45) | PDE4AMEN1KMT2AASAH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | PDE4A 2361/4885MEN1 1529/4885KMT2A 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.